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The only licensed vaccine against tuberculosis (TB), bacille Calmette–Guérin (BCG), 
protects against severe extrapulmonary forms of TB but is virtually ineffective against 
the most prevalent form of the disease, pulmonary TB. BCG was genetically modi-
fied at the Max Planck Institute for Infection Biology to improve its immunogenicity by 
replacing the urease C encoding gene with the listeriolysin encoding gene from Listeria 
monocytogenes. Listeriolysin perturbates the phagosomal membrane at acidic pH. 
Urease C is involved in neutralization of the phagosome harboring BCG. Its depletion 
allows for rapid phagosome acidification and promotes phagolysosome fusion. As a 
result, BCGΔureC::hly (VPM1002) promotes apoptosis and autophagy and facilitates 
release of mycobacterial antigens into the cytosol. In preclinical studies, VPM1002 has 
been far more efficacious and safer than BCG. The vaccine was licensed to Vakzine 
Projekt Management and later sublicensed to the Serum Institute of India Pvt. Ltd., the 
largest vaccine producer in the world. The vaccine has passed phase I clinical trials 
in Germany and South Africa, demonstrating its safety and immunogenicity in young 
adults. It was also successfully tested in a phase IIa randomized clinical trial in healthy 
South African newborns and is currently undergoing a phase IIb study in HIV exposed 
and unexposed newborns. A phase II/III clinical trial will commence in India in 2017 to 
assess efficacy against recurrence of TB. The target indications for VPM1002 are new-
born immunization to prevent TB as well as post-exposure immunization in adults to 
prevent TB recurrence. In addition, a Phase I trial in non-muscle invasive bladder cancer 
patients has been completed, and phase II trials are ongoing. This review describes the 
development of VPM1002 from the drawing board to its clinical assessment.
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Abbreviations: AIM2, absent in melanoma 2; BCG, bacille Calmette–Guérin; CFUs, colony forming units; CTL, human 
cytotoxic lymphocyte; DC, dendritic cell; EPI, expanded program of immunization; GBP, guanylate binding protein; HEU, 
HIV-exposed uninfected; IgG, immunoglobulin G; LC3, microtubule-associated protein light chain 3; LLO, listeriolysin O; 
MHC, major histocompatibility complex; Mtb, Mycobacterium tuberculosis; NLRP3, NLR family pyrin domain-containing 3; 
NMIBC, non-muscle-invasive bladder cancer; rBCG, recombinant BCG; RD1, Region of Difference 1; SCID, severe combined 
immunodeficiency; STING, stimulator of interferon genes; TB, tuberculosis; TCM, central memory T cells; TEM, effector memory 
T cells; TFH, follicular T cells; Th, T helper cell.
FiGURe 1 | Schematic overview of the development of the VPM1002 vaccine candidate. Clinical trials are labeled by their ClinicalTrials.gov Identifier number.
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iNTRODUCTiON
Infection with Mycobacterium tuberculosis (Mtb) led to 10.4 
million recorded cases of tuberculosis (TB) in 2015, with 1.8 
million recorded deaths [World Health Organization (WHO) 
report 2016]. The current therapy involves 6–9  months of 
antibiotics, with the emergence of multiple drug resistant 
strains being a continuing obstacle. An attenuated form of the 
bovine Mycobacterium species, Mycobacterium bovis bacille 
Calmette–Guerin (BCG) has been in clinical use since 1921 
and remains the only licensed vaccine against TB. BCG partially 
protects against TB meningitis and disseminated TB in infants 
and has non-specific immunostimulatory effects (1), which 
reduce general infant mortality by enhancing responses to 
other infectious diseases (2, 3). However, in all age groups, BCG 
does not adequately protect against pulmonary TB, the most 
prevalent form of disease and the route of disease transmission. 
In addition, BCG can cause severe adverse effects in immuno-
compromised individuals (4) and hence is contraindicated in 
HIV-infected individuals, the group that is most vulnerable to 
TB. However, in the absence of an alternative, BCG continues 
to be used in the immunization programs of several countries. 
To overcome these issues, several TB vaccine candidates are 
under development (5). One of the most advanced among them 
is BCG ΔureC::hly (VPM1002) (6).
VPM1002 is a recombinant BCG (rBCG) in which the urease 
C gene has been replaced by the listeriolysin O (LLO) encoding 
gene (hly) from Listeria monocytogenes (7). Urease C drives neu-
tralization of phagosomes containing mycobacteria by generation 
of ammonia, thereby inhibiting phagolysosomal maturation and 
contributing to the survival of mycobacteria inside the mac-
rophage (8, 9). Its depletion allows for rapid phagosome acidifi-
cation, which promotes phagolysosome fusion and provides the 
optimal pH for LLO stability (10). LLO is a cholesterol-dependant 
cytolysin that forms transmembrane β-barrel pores in the phago-
lysosome membrane, allowing escape of L. monocytogenes into 
the cytosol (10, 11). Its expression in VPM1002 results in the 
release of antigens and bacterial DNA into the cytosol, triggering 
autophagy, inflammasome activation, and apoptosis. VPM1002 
has demonstrated substantially increased immunogenicity, effi-
cacy, and safety in preclinical studies, successfully passed Phase 
I and II clinical trials, and will now enter a Phase II/III clinical 
trial in India in 2017. This review summarizes the development, 
preclinical, and clinical testing of VPM1002 (Figure 1).
3Nieuwenhuizen et al. The rBCG Vaccine VPM1002
Frontiers in Immunology | www.frontiersin.org September 2017 | Volume 8 | Article 1147
DeSiGN AND GeNeRATiON OF vPM1002
The attenuation of BCG was achieved by passaging virulent M. 
bovis in bile-containing medium for 13 years in the laboratory 
(12), during which time several genome segments were lost, 
including a segment known as Region of Difference 1 (RD1) 
which encodes the unique mycobacterial ESX-1 type VII 
secretion system (13, 14). ESX-1-dependent perturbation of 
host cell membranes requires direct contact with pathogenic 
mycobacteria such as Mtb, allowing the bacilli or their antigens 
to egress the phagosome into the cytosol (15). Mtb antigens 
are thus accessible to both the endocytic major histocompat-
ibility complex (MHC) class II antigen presentation pathway 
and the MHC I antigen presentation pathway in the cytosol, 
and consequently can stimulate CD4+ and CD8+ T-cell subsets, 
respectively, both of which are required for optimal protection 
against TB (16–21). In addition, ESX-1 dependent release of 
Mtb DNA into the cytosol can be detected by host sensors, 
leading to activation of NLR family pyrin domain-containing 
3 (NLRP3) and absent in melanoma 2 inflammasomes, release 
of interferons, increased autophagy and apoptosis (22–25). 
Induction of apoptosis in infected host cells generates vesicles 
carrying mycobacterial antigens that can be phagocytosed 
by bystander antigen presenting cells, mainly dendritic cells 
(DCs) and trafficked through MHC I antigen processing 
pathways to stimulate CD8+ T  cells in a process known as 
cross-priming (26, 27). Mice with deficient cross-presentation 
due to the absence of annexin 1 show impaired Mtb-specific 
CD8+ T cells and are highly susceptible to TB (28). Lacking the 
ESX-1 secretion system, BCG is restricted to the phagosome 
of host cells, therefore its antigens and bacterial DNA do not 
enter the cytosol and the antigens are primarily processed by 
MHC class II pathways, stimulating CD4+ T  cell responses 
(13, 14, 29, 30). BCG induces only weak apoptosis and CD8+ 
T cell responses (26). Furthermore, both BCG and Mtb inhibit 
surface MHC II expression, as urease-dependent alkalinization 
of the phagosome causes intracellular sequestration of MHC II 
dimers, resulting in suboptimal CD4+ T cell responses (31–33). 
Phagosomal biology is therefore a clear target for interventions 
aimed at enhancing T cell responses against mycobacteria.
Originally, VPM1002 was designed to improve accessibility 
of mycobacterial antigens to the MHC I pathway via cytosolic 
egression of antigens mediated by LLO perturbation of phago-
somal membranes in order to improve induction of CD8+ 
T cells by the parental BCG strain (34, 35). In addition, leakage 
of phagolysosomal proteases such as cathepsins into the cytosol 
could activate caspases, leading to apoptosis and subsequent 
cross-presentation of mycobacterial antigens, which promotes 
both MHC I and MHC II restricted T  cell stimulation (36). 
Studies with L. monocytogenes have shown that pore formation 
by LLO also triggers many downstream effects such as activation 
of the NLRP3 inflammasome, induction of cytokine expression, 
activation of kinases, triggering of endocytosis, histone modifica-
tion and release of calcium from intracellular stores (37). An Hly 
recombinant strain, hly+ rBCG+, was generated by integrating 
the hly gene into BCG using the mycobacteria-Escherichia coli 
shuttle vector pMV306 (34). LLO was detected in the membrane 
structures, phagosomal space, and cytoplasmic vacuoles of 
macrophages infected with BCG pMV306::hly, and intracel-
lular persistence of this strain was reduced compared with the 
parental BCG strain. MHC I presentation of co-phagocytosed 
soluble protein was improved in macrophages infected with this 
strain compared to BCG (34) and an in vitro human cytotoxic 
T lymphocyte (CTL) assay using cultured DCs and T cells from 
healthy human donors demonstrated that hly+ BCG infection 
was better at inducing CTL responses than BCG infection (38). 
In the next generation strain, deletion of ureC was performed 
to ensure an optimal (acidic) pH for LLO stability; however, 
absence of ureC also promotes MHCII trafficking to the mac-
rophage surface (31), which would also stimulate CD4+ T cell 
responses. To generate ΔureC hly+ BCG, the chromosomal inte-
grative shuttle vector pMV306hyg-hly (8) was used to transform 
M. bovis BCG ΔureC::aph, and hygromycin-resistant clones 
were selected (35). The vaccine was licensed to Vakzine Projekt 
Management, and named “VPM1002.” The resistance cassette 
was subsequently successfully removed, although VPM1002 
is equally sensitive to the antimycobacterial agents isoniazid, 
rifampicin, and ethambutanol in the presence or absence of the 
hygromycin resistance gene (39).
HOST CeLL ReSPONSeS TO vPM1002  
IN VITRO
Increased quantities of mycobacterial antigen were detected in 
VMP1002 infected macrophages compared to BCG infected 
macrophages (35), and mycobacterial DNA was detected only 
in the cytosol of VPM1002 infected but not BCG infected 
macrophages (29), indicating that expression of LLO in BCG 
ΔureC::hly allows the escape of bacterial products to the cytosol, 
presumably by perturbation of the phagosomal membrane. The 
bacteria themselves do not escape to the cytosol, unlike Mtb 
bacilli (29, 35). Infection of primary human and mouse mac-
rophages demonstrated increased apoptosis after infection with 
VPM1002 compared to both BCG and BCG::hly, demonstrating 
the additional benefit of urease C deletion (35). Membrane 
disruption can facilitate the release of phagolysosomal proteases 
such as cathepsins into the cytosol, which are known to induce 
apoptosis (36, 40). Both the presence of mycobacterial proteins 
in the cytosol and the induction of apoptosis by perforation of 
the phagosomal membrane could cause increased trafficking 
of antigens to MHC I pathways (35). Apoptosis results in an 
increase in both CD8+ and CD4+ T cell responses in mycobacte-
rial infection, suggesting that DCs may transfer efferocytosed 
antigens to the endocytic system (27, 36). The priming potential 
of apoptotic vesicles isolated from BCG and VPM1002 infected 
mouse macrophages was investigated in a co-culture system with 
splenic DCs and T cells, and VPM1002-infected apoptotic vesi-
cles induced more profound CD4+ and CD8+ T cell responses 
compared to those infected with BCG (41). Vesicles from 
VPM1002 infected macrophages also induced higher produc-
tion of the T helper type (Th)17-polarizing cytokines interleukin 
(IL)-6 and IL-23, and the immunoregulatory cytokine IL-10 by 
bone marrow-derived DCs.
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Experiments in THP1 macrophages demonstrated that 
VPM1002 infection leads to activation of multiple caspases (29). 
The apoptotic effector caspases 3 and 7 were highly activated by 
VPM1002 in comparison to BCG, as well as caspase 1, which 
mediates pyroptosis, an inflammatory form of cell death and 
is an important regulator of the inflammatory response (42). 
Inflammasomes are multi-protein complexes composed of 
intracellular sensors and caspase 1. They control activation of 
caspase 1, which in turn cleaves the precursors of the cytokines 
IL-1β and IL-18 into their active forms (43). VPM1002 infection 
increased production of IL-1β and IL-18, which was dependent 
on AIM2 inflammasome activation but not on NLRP 1 and 3 
inflammasome activation. Furthermore, VPM1002 induced 
increased levels of the autophagy marker microtubule-associated 
protein light chain 3 in an AIM2- and stimulator of interferon 
genes (STING)-dependent manner. The AIM2 inflammasome 
senses cytosolic DNA and is involved in the induction of caspase 
1-dependent pyroptosis (44, 45), while STING acts as an essential 
adaptor protein in the induction of autophagy by cytosolic DNA 
(25). Autophagy, a protein degradation process induced by stress 
conditions such as infection, promotes the delivery of cytosolic 
antigens to MHC trafficking pathways (46, 47). It has also been 
shown to contribute to innate immunity against mycobacteria 
and other intracellular pathogens (48, 49). While autophagy 
was originally thought to be non-specific, it is now known that 
it can selectively target intracellular pathogens in a process 
known as xenophagy that involves ubiquitination of pathogen 
proteins or pathogen-containing endosomes (50). Intriguingly, 
gene expression of guanylate-binding proteins (GBPs) was also 
elevated in VPM1002 infected THP-1 macrophages compared 
to BCG infected macrophages. Interferon-inducible GBPs have 
multiple roles in inflammasome activation, autophagy, and lysis 
of pathogen-containing vacuoles and can even directly target 
the pathogens themselves (51–54). Whether they play a role in 
the translocation of mycobacterial components from the phago-
some into the cytosol during VMP1002 infection remains to be 
determined.
Disruption of the VPM1002-containing phagosome mem-
brane by LLO and release of mycobacterial DNA into the cytosol 
appears to have effects in inducing immune responses that are 
similar to the effects of ESX-1 activity in Mtb or M. marinum. 
ESX-1 of M. marinum stimulates autophagosome formation and 
recruitment to the vacuole; however, unlike LLO it also inhibits 
autophagic flux, thereby preventing bacterial degradation (49). 
Testing of vaccine candidates expressing ESX-1 such as Mtb 
Δppe25-pe19 (55) and BCG expressing ESX-1 of M. marinum 
(BCG:ESX-1Mmar) (56) demonstrated that ESX-1 was critical for 
enhancing innate immune responses via phagosome rupture. 
BCG:ESX-1Mmar induced the cGas/STING/TBK1/IRF-3/type I 
interferon axis and promoted AIM2 and NLRP3 inflammasome 
activation, resulting in increased frequencies of antigen-specific 
CD8+ and CD4+ T  cells and increased protection against Mtb 
compared to BCG (56), while Mtb Δppe25-pe19 also led to 
enhanced protection. ESX-1 may induce protective immunity 
by an additional mechanism, as ESAT6 is required for rapid, 
non-cognate IFN-γ production by CD8+ T cells, mediated by the 
NLRP3/caspase-1/IL-18 axis (57).
PReCLiNiCAL eFFiCACY AND SAFeTY
Aerosol challenge of vaccinated BALB/c or C57BL6 mice with 
100–200 colony-forming units (CFUs) of Mtb H37Rv or a clini-
cal isolate of the Beijing/W genotype family demonstrated that 
VPM1002 immunization has significantly greater protective 
efficacy than the parental BCG strain, with bacterial loads in 
the lungs typically reduced by one to two logs in late stages 
of infection (35, 58–61). In a low dose infection (30  CFU), 
VPM1002 led to an almost 1000-fold reduction of Mtb in the 
lungs compared to naïve mice at day 200 after infection (35). 
Homologous boosting with VPM1002 did not improve protec-
tion compared to a single immunization (60). However, a post-
exposure vaccination model using antibiotics for an extended 
period and then allowing bacterial regrowth demonstrated that 
mice with subclinical TB had lower bacterial burdens when 
vaccinated with VPM1002 compared to BCG, suggesting that 
VPM1002 could also be considered for use as a post-exposure 
vaccine (60).
The safety profile of VPM1002 has been evaluated in animal 
models including mice, guinea pigs, rabbits, and non-human 
primates (6). In RAG1-/- immunodeficient mice lacking mature 
T and B cells, bacterial loads were not significantly different in 
lungs and spleen after vaccination with VPM1002 compared 
to BCG (35). However, VPM1002 demonstrated substantially 
lower virulence in severe combined immunodeficiency mice, 
most likely due to the reduced intracellular persistence of 
this strain (35, 61). After immunization of wildtype BALB/c 
or C57BL6 mice, VPM1002 was more rapidly cleared from 
the draining lymph nodes than BCG and disseminated less 
to the spleens, where it was also quickly cleared (59, 61). 
Dissemination to the lungs was observed in BCG vaccinated 
but not VPM1002 vaccinated mice. Enhanced adaptive 
immune responses after VPM1002 vaccination are therefore 
likely to play a role in the reduced dissemination of VPM1002 
in immunocompetent mice. Overall, the data demonstrate 
increased safety and protective efficacy of VPM1002 compared 
to parental BCG in mice.
In guinea pigs and non-human primates, the safety of 
VPM1002 was comparable to that of BCG (6, 39). As the pri-
mary target population for vaccination against TB is newborns, 
the safety profiles of VPM1002 and BCG were also compared in 
newborn rabbits (39). No dissemination to tissues was observed 
after VPM1002 administration, and the body weight gain was not 
affected during the 90 days observation period, whereas the body 
weight was reduced in the BCG vaccinated group compared to 
the saline control group. No premature mortality was observed in 
either group. The preclinical safety of VPM1002 is thus supported 
by a large body of evidence.
ANALYSiS OF iMMUNe ReSPONSeS  
TO vPM1002 iN MiCe
Analysis of gene expression in mice early after immunization 
with VPM1002 demonstrated that, as in THP-1 cells, expres-
sion of IL-18 and IL-1β was increased, as well as expression 
of IFN-inducible genes such as Tmem173 (STING), Gbp’s, 
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and other GTPases (29, 61). Apoptosis was increased in the 
lymph nodes of VPM1002 immunized mice compared with 
BCG immunized mice by day 14 (61). Immunization with 
VMP1002 induced both type 1 and type 17 cytokine responses 
in mice, whereas BCG induced type 1 responses only (58). After 
restimulation with PPD, levels of IFN-γ, IL-17, IL-2, IL-6, and 
GM-CSF were increased in lung cells isolated from VPM1002 
immunized mice compared to those from BCG immunized 
mice, and splenocytes from VPM1002-vaccinated mice also 
produced more IL-17. Furthermore, percentages of γδ T cells 
producing IFN-γ and IL-17 were increased after vaccination 
with VPM1002 (58). Seven days after Mtb challenge, IL-2+TNF+ 
double cytokine producing cells were increased in the lungs of 
VPM1002-immunized mice compared with BCG-vaccinated 
mice, suggesting recall responses, because newly generated 
T cells take 12–14 days to reach the lungs during Mtb infection 
(62). IL-2+TNF+ CD4+ T cells typically show a central memory 
phenotype (TCM) (21), and further studies demonstrated that 
VPM1002 immunization indeed induces higher frequencies 
of TCM than immunization with BCG (59, 61). Ag85B-specific 
CD4+ TCM were significantly increased in the draining lymph 
nodes of VPM1002-vaccinated compared to BCG-vaccinated 
mice at day 14 (59).
Bacille Calmette–Guérin induces effector memory CD4+ 
T (TEM) cells that can control acute infection but appears to 
induce insufficient numbers of TCM cells for long-term protec-
tion (21). Transfer studies demonstrated that TCM cells from 
VPM1002 infected mice conferred protection against TB infec-
tion whereas TEM, T follicular helper (TFH), and naïve T cells did 
not, at least at the numbers of cells tested (59). These findings 
concur with other studies in which TCM cells were associated 
with protection (21). While TEM cells appear early after infection 
and provide protection by the secretion of effector cytokines 
such as IFN-γ and TNF-α, TCM cells proliferate in the LN and 
generate new pools of TEM cells after re-exposure to antigen (59, 
63, 64). The TCM cells generated by subcutaneous vaccination 
with VPM1002 or BCG were found to reside over the long term 
in the secondary lymphoid organs, rather than in the lung, and 
to be recruited to the lungs after Mtb challenge (58, 59). Waning 
of BCG-induced immunity correlates with a decline in T cell 
functions such as cytokine production and CTL activity and 
an increase in terminally differentiated, dysfunctional T  cells 
(65). Thus, systemic maintenance of TCM populations over the 
long term and the rapid recruitment of TCM cells to the lung 
following Mtb infection remains a key goal in the develop-
ment of more effective vaccine candidates (59). VPM1002 also 
induced an increase in mycobacteria-specific immunoglobulin 
G levels after vaccination compared to BCG, and a concomitant 
increase in CXCR5-expressing TFH cells (59, 61), which have 
been associated with decreased lung pathology (66) and stimu-
late germinal center B  cell responses (63). Passive transfer of 
serum from VPM1002- or BCG-immunized mice on the day of 
Mtb infection and thrice weekly did not reduce bacterial load at 
day 14 (59), but growing evidence suggests that antibodies may 
play a role in protection against Mtb (67–71). Overall, increased 
protection conferred by VPM1002 immunization in the mouse 
model was associated with increased numbers of TCM and TFH 
cells, increased Th17 responses, earlier recruitment of T cells 
to the lungs following Mtb challenge and increased levels of 
anti-mycobacterial antibodies (58, 59, 61).
CLiNiCAL TRiALS wiTH vPM1002: A STeP 
TOwARD A SAFeR, MORe eFFiCACiOUS 
TB vACCiNe
Human data on VPM1002 are available from three clinical trials, 
all performed with the original hygromycin-resistant strain of 
VPM1002. Two Phase I studies were performed in healthy adult 
volunteers, and one Phase IIa study was conducted in healthy 
newborn infants, one of the intended target populations. In 
the first Phase I clinical trial (ClinicalTrials.gov Identifier: 
NCT00749034) conducted in Germany, healthy Caucasian 
adult males with (W) or without (WO) a history of BCG vac-
cination received VPM1002 randomized to three escalating 
doses (N = 30W + 30WO) or BCG at the standard vaccine dose 
(N =  10W +  10WO) and were followed for 6  months. Single 
vaccination with VPM1002 up to 5 ×  10e5 CFU was safe and 
well tolerated. The immunogenicity of VPM1002 as measured 
by IFN-γ release by stimulated T cells was dose dependent. Both 
VPM1002 and BCG induced multifunctional CD4+ and CD8+ 
T  cell subsets, which are thought to play a role in protection 
against TB (72–74), with VPM1002 showing an earlier increase 
in double and triple cytokine producing T cells which remained 
at heightened levels throughout the study (7). Furthermore, only 
VPM1002 induced serum antibodies against mycobacterial anti-
gens (7), echoing preclinical studies in which VPM1002 induced 
higher levels of mycobacteria-specific antibodies than BCG in 
mice (59, 61). In the second Phase I clinical trial (ClinicalTrials.
gov Identifier: NCT01113281), performed in South Africa, 24 
healthy male and female adults with a history of BCG immuni-
zation, predominantly from the indigenous African population, 
were vaccinated with VPM1002. The study showed that a single 
vaccination with VPM1002 is safe, well tolerated and elicits a 
profound immune response in an African adult population (6).
The Phase IIa clinical trial (ClinicalTrials.gov Identifier: 
NCT01479972) was the first investigation of VPM1002 in 
newborns (75). It was conducted in Cape Town, South Africa, 
a region with a high TB burden. Forty-eight HIV-unexposed, 
newborn infants were vaccinated with either VPM1002 (n = 36) 
or BCG (n = 12) through an open label, randomized, controlled 
design. Polyfunctional CD4+ and CD8+ T  cell responses were 
similar between the groups, and both groups had increased 
IFN-γ responses after 7  h PPD stimulation at all measured 
time points post vaccination compared to baseline. Both vac-
cines induced IL-17 responses; though, unlike BCG, VPM1002 
induced increased proportions of CD8+ IL-17+ T cells at day 14 
and month 6 time points compared to the baseline. The incidence 
of abscess formation was lower for VPM1002 compared to BCG. 
Thus, VPM1002 was safe, well tolerated, and immunogenic in 
newborn infants.
In addition, a Phase IIb clinical trial is currently ongoing in 
South Africa (ClinicalTrials.gov Identifier: NCT02391415). This 
trial is a double-blind, randomized, controlled study to evaluate 
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the safety and immunogenicity of VPM1002 in comparison with 
BCG in HIV-exposed uninfected (HEU) and HIV-unexposed, 
BCG-naive newborn infants. The inclusion of HEU infants in the 
trial is important, as this group comprises 30% of the newborns 
requiring BCG vaccination in South Africa, and they may be at 
higher risk of Mtb infection than HIV-unexposed infants. The 
proportion of HEU may vary in different countries. Previous 
work from Brazil suggests that HEU infants have poorer T-cell 
proliferation and lower levels of IFN-γ production compared to 
HIV-unexposed infants (76). Enrollment of 416 infants has been 
completed and follow-up is in progress. Follow-up will continue 
for 12 months, as opposed to 6 months in NCT01479972, ena-
bling collection of preliminary efficacy data.
In addition to its development as a vaccine for newborns, 
VPM1002 is also being assessed as a post-exposure vaccine for 
adults, since preclinical studies in mice demonstrated that it 
reduced bacterial loads in a post exposure model (60). A phase 
II/III trial has received regulatory approval by the Indian authori-
ties. Once ethics committee approvals are received for all sites, 
the trial will commence across India (ClinicalTrials.gov Identifier: 
NCT03152903). The study will be conducted in 2000 adults who 
were TB patients, but received drug treatment and were cured of 
disease. In such populations, there is a high risk of recurrence 
(including re-infection and relapse), especially within 12 months 
after completing treatment. The multi-centric, placebo-controlled, 
randomized, controlled study will assess whether VPM1002 can 
prevent such TB recurrence over a 1-year follow-up period. 
Currently, no intervention is licensed for this indication, includ-
ing BCG, which means there is clearly an unmet medical need. 
The study will also expand the safety database on VPM1002.
evALUATiON OF vPM1002 AS A BLADDeR 
CANCeR THeRAPY
Bladder cancer is the ninth most common cancer in the world, 
and is four times more common in men than in women (77). The 
main risk factors for developing bladder cancer include smoking, 
Schistosoma infection (bilharzia), and exposure to industrial 
chemicals (77, 78). Tumors can be non-muscle invasive, i.e., con-
fined to the mucosa of the bladder wall, or muscle-invasive. More 
than seventy percent of bladder cancers are detected while they 
are still non-muscle invasive (79). Due to its immunostimulatory 
properties, repeated intravesical BCG instillation is the standard 
adjuvant treatment for intermediate to high-risk non-muscle-
invasive bladder cancer (NMIBC) after transurethral resection of 
the tumors (80–82). BCG therapy reduces the risk of recurrence 
and the progression to muscle invasive bladder cancer. The repeated 
instillations require much higher doses and volumes of BCG than 
vaccination against TB does, and some patients have adverse 
events that lead to discontinuation of the therapy (83, 84). Adverse 
events include fever, bladder irritation, decreased bladder capacity, 
incontinence, hematuria, flu-like symptoms and in approximately 
5% of cases, BCG infection (85, 86). Patients undergoing traumatic 
catheterization are at risk for intraluminal BCG dissemination, 
resulting in a potentially lethal systemic infection (87).
The precise immune mechanisms by which BCG promotes 
anti-tumor activity in bladder cancer are not completely resolved, 
but it is well-established that the ability of BCG to promote Th1 
responses is important, as well as the recruitment of neutrophils 
and innate lymphocytes including natural killer cells (82, 88, 
89). Activation of immune cells may lead to elimination of the 
urothelial cancerous cells that have internalized BCG (82, 90). 
Increased CD4+ T  cell responses have been measured during 
BCG therapy, and BCG was shown to promote secretion of both 
Th1- and Th2-type cytokines (88, 91–93). A positive response to 
BCG therapy (no recurrence or evidence of disease during follow-
up examinations) has been associated with an intratumoral Th2 
predisposition (increased GATA3) and decreased concentrations 
of IL-10, combined with a Th1 functional phenotype indicated by 
increased levels of Th1-related inflammatory metabolites (88). In 
another study, increased regulatory T cells and tumor-associated 
macrophages in the tumor microenvironment were also associ-
ated with non-responsiveness, while increased GATA3+ and CD4+ 
T cells were associated with responders (88, 94). BCG Connaught 
conferred greater 5-year recurrence-free survival than BCG Tice 
and induced stronger Th1 type responses, BCG-specific CD8+ 
T cells and T cell recruitment to the bladder (93). Genetic analysis 
demonstrated several differences between the two strains, includ-
ing the absence of RD15 in BCG Connaught (93).
Because approximately 30–40% of patients do not respond to 
BCG therapy and others suffer from adverse events, rBCG tech-
nology has been tested for improving the efficacy and tolerability 
of BCG in bladder cancer therapy (82). rBCGs that have been 
modified to express immunostimulatory molecules, cytokines, 
or antigens have been tested in mice for their capacity to induce 
stronger and more specific immune responses. VPM1002 is cur-
rently being evaluated in SAKK 06/14, a Phase I/II trial for immu-
notherapy in patients with NMIBC (ClinicalTrials.gov Identifier: 
NCT02371447). The phase I part of the trial has been completed 
in Switzerland. Intravesical application of VPM1002BC dem-
onstrated that the product is safe and well tolerated in NMIBC 
patients. The recommended phase II dose has been established as 
1–19.2 × 10e8 CFUs of VPM1002BC. The phase II part has been 
approved by the Swiss and German regulatory authorities and is 
currently ongoing in both countries.
OUTLOOK
The available preclinical and clinical data reveal that VPM1002 
is immunogenic and may be better than BCG in terms of safety. 
VPM1002 could be a safe, well-tolerated and efficacious alterna-
tive to the BCG vaccine in the future. With an annual capacity 
of 100 million doses, Serum Institute of India Pvt. Ltd. can meet 
the global demand for a BCG vaccine and is well poised to supply 
the new vaccine if efficacy trials are successful. While this vaccine 
progresses through efficacy trials, next-generation derivatives are 
being designed and tested in preclinical models aimed at optimiz-
ing efficacy and/or safety (61, 95). Furthermore, VPM1002 is 
currently being tested in goats by the Friedrich Loeffler Institute 
in Germany for the prevention of M. caprae infection (Menge et al. 
unpublished data). Infections with M. caprae and M. bovis, closely 
related species of the same clade that cause TB in goats and cattle, 
respectively, are of agricultural importance, and can potentially be 
transmitted to humans (96, 97).
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Almost 100  years after the first immunization with BCG, a 
rBCG vaccine candidate is ready for clinical efficacy testing. This 
marks a major step forward in the long journey that began when 
the recombinant vaccine was constructed in the late 1990s and 
tested in different animal models to determine its safety and 
protective effect.
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